More than a dozen leading artificial intelligence companies have issued a joint letter to the US Congress calling for mandatory biosecurity safeguards, marking the first time the industry’s fiercest competitors have aligned on existential risk mitigation measures.
The signatories—including OpenAI, Anthropic, Google DeepMind, Meta, and Microsoft—are urging lawmakers to establish federal requirements for AI systems that could accelerate the development of biological weapons, according to reports from The Verge, TechCrunch, and Ars Technica. The letter represents a notable departure from the sector’s typically fragmented approach to regulation.
The companies are specifically requesting that Congress mandate pre-deployment biosecurity evaluations for advanced AI models, alongside ongoing monitoring systems to detect misuse. The proposal would require firms to demonstrate that their systems cannot be readily exploited to design novel pathogens or circumvent existing biological safety protocols.
“This is the clearest signal yet that the industry recognises it cannot self-regulate on catastrophic risks,” said one policy analyst familiar with the letter’s contents. The coordinated approach follows months of behind-the-scenes discussions among chief executives and safety teams across competing organisations.
The timing coincides with growing congressional interest in AI safety legislation. At least three separate bills addressing AI-enabled biosecurity threats are currently in committee, though none have advanced to floor votes. The industry’s unified stance could provide political cover for legislators hesitant to impose requirements on a strategically important sector.
The letter arrives as recent research has demonstrated that large language models can provide detailed guidance on synthesising dangerous biological agents to users with minimal scientific expertise. One study found that advanced AI systems reduced the time required to identify potential pandemic pathogens by approximately 40 per cent compared to traditional research methods.
Business impact
The proposed framework would disproportionately affect smaller AI laboratories and open-source projects, which typically lack the infrastructure for comprehensive biosecurity testing. Established players like OpenAI and Google already maintain dedicated safety teams and can absorb compliance costs more readily than venture-backed startups.
The accord may also pre-empt more stringent regulatory proposals. By proposing industry-informed standards, the signatories are effectively shaping the regulatory landscape before external mandates are imposed. This strategy mirrors approaches used by pharmaceutical and financial services sectors when facing increased scrutiny.
For investors, the unified stance reduces regulatory uncertainty—a persistent concern in AI valuations. Markets have responded positively to previous instances of industry self-organisation, viewing coordination as evidence of sector maturity rather than competitive weakness.
However, the proposal notably omits specific technical standards or enforcement mechanisms, leaving substantial room for interpretation. The letter recommends that the National Institutes of Health and the Department of Homeland Security develop detailed evaluation protocols, but does not commit to particular testing methodologies or failure thresholds.
Open-source advocates have raised concerns that mandatory pre-deployment reviews could effectively ban public model releases, concentrating power among well-resourced corporations. The letter does not address how biosecurity requirements would apply to models released under permissive licences or developed by academic institutions.
What to watch
Congressional response will be the immediate test of the letter’s influence. Key committees including the Senate Commerce, Science, and Transportation Committee are expected to hold hearings on AI biosecurity within the next legislative session. Whether lawmakers adopt the industry’s proposed framework or pursue more aggressive measures will signal the balance of power between Silicon Valley and Washington on existential risk governance.
International coordination will also prove critical. The European Union’s AI Act already includes provisions for high-risk applications, though biological weapons prevention is not explicitly addressed. If the US establishes biosecurity standards, pressure will mount for harmonisation with allied nations to prevent regulatory arbitrage.
The accord represents a calculated bet by AI leaders that accepting targeted regulation on catastrophic risks can forestall broader constraints on model development. Whether this strategy succeeds in satisfying policymakers whilst preserving innovation capacity will shape the industry’s trajectory for years to come.
